FACULTY
Stephanie Taylor
Senior Associate Dean
Dean's Office - Administration
- staylo2@lsuhsc.edu
- Medicine
Academic Office:
LSU CrescentCare Sexual Health Center
3308 Tulane Avenue
New Orleans, LA 70119
Clinical Office:
LSU CrescentCare Sexual Health Center
3308 Tulane Ave, 5th Floor
New Orleans, LA 70119
Bio
Stephanie N. Taylor, MD is Professor of Medicine in the Section of Infectious Diseases at Louisiana State University Health Sciences Center, New Orleans, LA. She is board certified in both Internal Medicine and Infectious Diseases and her clinical practice and research focus on sexually transmitted infections, STI-related diagnostic trials and STI clinical drug trials. She has authored 6 book chapters and 80 journal publications, including one as lead author in the prestigious New England Journal of Medicine. Dr. Taylor is medical director of the LSU Infectious Diseases STD laboratory and the Louisiana Office of Public Health STD/HIV Program. After many years as medical director of the LSU STI Research Program and LSU-CrescentCare Sexual Health Center, these medical directorships are now held by Dr. Rebecca Lillis who has performed outstanding work as assistant medical director. Dr. Taylor is a past recipient of a Distinguished Career Achievement Award from the American STD Association and is an associate editor of Clinical Infectious Diseases, the flagship journal of the Infectious Diseases Society of America. Dr. Taylor is also a member of the NIH-National Institute of Allergy and Infectious Diseases Advisory Council (Microbiology and Infectious Diseases Subcommittee).
Education
Undergraduate:
1980 - B.S. in Medical Technology
University of New Orleans/ LSUMC School of Allied Health
New Orleans, Louisiana
Medical:
1988 - M.D.
Louisiana State University School of Medicine
New Orleans, Louisiana
Internship:
1988 - 1989 - Internal Medicine
Louisiana State University School of Medicine
New Orleans, Louisiana
Residency:
1989 - 1991 - Internal Medicine
Louisiana State University School of Medicine
New Orleans, Louisiana
Chief Residency:
1991 - 1992 - Internal Medicine
Louisiana State University School of Medicine
New Orleans, Louisiana
Fellowship:
1992 -1996 - Infectious Diseases
Louisiana State University School of Medicine
New Orleans, Louisiana
Affiliated Hospitals & Clinics
Ochsner Kenner Medical Center
Publications
1. Hook EW III, Golden MR, Taylor SN, Henry E, et.al. Efficacy and safety of single
dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea
treatment: an open-label, non-inferiority, Phase 3, multicenter, randomized study.
Sex Transm Dis. 2019;46:279-286.
2. Craig-Kuhn MC, Granade C, Muzny C, Van Der Pol B, Lillis R, Taylor SN, et. al. Optimal Timing for Trichomonas vaginalis Test of Cure Using Nucleic Acid
Amplification Testing. Sex Trans Dis. 2019;46:312-316.
3. Hook EM, Newman L, Drusano G, Handsfield H, Jerse AE, Kong FYS, Lee YY, Taylor SN, Deal C. Development of New Antimicrobials for Urogenital Gonorrhea Therapy: Clinical Trial Design Considerations. Clin Infect Dis. 2019 Sep 20. pii: ciz899. doi: 10.1093/cid/ciz899.
4. Gaydos CA, Manhart LE, Taylor SN, et al. Molecular Testing for Mycoplasma genitalium in the United States: Results from the AMES Prospective Multicenter Clinical Study. J Clin Microbiol. 2019 Oct 23;57(11):e01125-19. doi:10.1128/JCM.01125-19. Print 2019 Nov. PMID: 31484702
5. Schwebke JR, Taylor SN, Ackerman R, et al. Clinical validation of the Aptima Bacterial Vaginosis and Aptima Candida/Trichomonas 2 Vaginitis Assays: results from a prospective multi-center clinical study. J Clin Microbiol. 2020 Jan 28;58(2):e01643-19. doi: 10.1128/JCM.01643-19. Print 2020 Jan 28. PMID: 31748322
6. Prevalence of Mycoplasma genitalium infection, antimicrobial resistance mutations and symptom resolution following treatment of urethritis. Bachmann LH, Kirkcaldy RD, …Taylor SN, et al. The MAGNUM Laboratory Working Group. Clin Infect Dis. 2020 Mar 18:ciaa293. doi: 10.1093/cid/ciaa293. Online ahead of print. PMID: 32185385
7. Evaluation of the Performance of a Point-of-Care Test for Chlamydia and Gonorrhea. Van Der Pol B, Taylor SN, Mena L, et. al. JAMA Netw Open. 2020 May 1;3(5):e204819. doi: 10.1001/jamanetworkopen.2020.4819. PMID: 32407506
8. Mycoplasma genitalium Detection in Urogenital Specimens from Symptomatic and Asymptomatic Men and Women by Use of the cobas TV/MG Test. Van Der Pol B, Waites KB, Xiao L, Taylor SN, et al. J Clin Microbiol. 2020 May 26;58(6):e02124-19. doi: 10.1128/JCM.02124-19. Print 2020 May 26. PMID: 32213558
9. Characteristics of Mycoplasma genitalium Urogenital Infections in a Diverse Patient Sample from the United States: Results from the Aptima Mycoplasma genitalium Evaluation Study (AMES) Manhart LE, Gaydos CA, Taylor SN, et al. J Clin Microbiol. 2020 Jun 24;58(7):e00165-20. doi: 10.1128/JCM.00165-20. Print 2020 Jun 24. PMID: 32321783
10. Resistance-Guided Treatment of Gonorrhea: A Prospective Clinical Study. Klausner JD, Bristow CC, …Taylor SN, et al. Clin Infect Dis. 2020 Aug 7:ciaa596. doi: 10.1093/cid/ciaa596. Online ahead of print. PMID: 32766725.
11. Young S, Taylor SN, Cammarata CL, Varnado KG, et al. Clinical Evaluation of BD Veritor SARS-CoV-2 Point-of-Care Test Performance Compared to PCR-Based Testing and versus the Sofia 2 SARS Antigen Point-of-Care Test. J Clin Microbiol. 2020 Dec 17;59(1):e02338-20. doi: 10.1128/JCM.02338-20. Print 2020 Dec 17.
12. Young S, Vaughan L, Yanson K,…..Taylor SN, et al. Analytical and Clinical Sample Performance Characteristics of the Onclarity Assay for the Detection of Human Papillomavirus. J Clin Microbiol. 2020 Dec 17;59(1):e02048-20. doi: 10.1128/JCM.02048-20. Print 2020 Dec 17.
13. Kalil AC, Patterson TF, Mehta AK, et al. (Site Principal Investigators listed in Acknowledgements) Baricitinab plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021 Mar 4;384(9):795-807.doi:10.1056/NEJMoa2031994.Epub2020 Dec 11.PMID: 33306283.
14. Kalil AC, Patterson TF, Mehta AK, et al. (Site Principal Investigators listed in Acknowledgements)Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. The Lancet Respiratory. 2021 Oct 18 Epub202